$178.14
0.45% day before yesterday
NYSE, Nov 28, 09:30 pm CET

Charles River Laboratories International, Inc. Stock price

$178.14
-9.79 5.21% 1M
+41.89 30.75% 6M
-6.46 3.50% YTD
-21.45 10.75% 1Y
-58.97 24.87% 3Y
-56.38 24.04% 5Y
+101.57 132.65% 10Y
+133.55 299.51% 20Y
NYSE, Closing price Fri, Nov 28 2025
-0.80 0.45%

Key metrics

Basic
Market capitalization
$8.8b
Enterprise Value
$10.7b
Net debt
$2.0b
Cash
$207.2m
Shares outstanding
49.2m
Valuation (TTM | estimate)
P/E
negative | 17.3
P/S
2.2 | 2.2
EV/Sales
2.7 | 2.7
EV/FCF
19.8
P/B
2.6
Financial Health
Equity Ratio
46.0%
Return on Equity
0.3%
ROCE
7.4%
ROIC
25.3%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$4.0b | $4.0b
EBITDA
$671.4m | $1.0b
EBIT
$472.1m | $771.8m
Net Income
$-83.5m | $506.4m
Free Cash Flow
$543.7m
Growth (TTM | estimate)
Revenue
-0.9% | -0.5%
EBITDA
-9.5% | 49.0%
EBIT
-22.7% | 40.1%
Net Income
-120.2% | 4,816.4%
Free Cash Flow
-3.0%
Margin (TTM | estimate)
Gross
34.7%
EBITDA
16.7% | 25.5%
EBIT
11.7%
Net
-2.1% | 12.6%
Free Cash Flow
13.5%
More
EPS
$-1.7
FCF per Share
$11.0
Short interest
6.3%
Employees
19k
Rev per Employee
$210.0k
Show more

Is Charles River Laboratories International, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Charles River Laboratories International, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Charles River Laboratories International, Inc. forecast:

11x Buy
48%
12x Hold
52%

Analyst Opinions

23 Analysts have issued a Charles River Laboratories International, Inc. forecast:

Buy
48%
Hold
52%

Financial data from Charles River Laboratories International, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,024 4,024
1% 1%
100%
- Direct Costs 2,628 2,628
1% 1%
65%
1,395 1,395
4% 4%
35%
- Selling and Administrative Expenses 724 724
1% 1%
18%
- Research and Development Expense - -
-
-
671 671
10% 10%
17%
- Depreciation and Amortization 199 199
52% 52%
5%
EBIT (Operating Income) EBIT 472 472
23% 23%
12%
Net Profit -83 -83
120% 120%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Charles River Laboratories International, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Charles River Laboratories International, Inc. Stock News

Neutral
Seeking Alpha
8 days ago
The small cap team initiated a new investment position in Hexcel Corporation. Hexcel is a global leader in advanced composite materials. We initiated a position in Charles River Labs in Q3. CRL is a high-quality company in the drug discovery and development outsourcing space. Small cap exited Saia this quarter. The company has faced a challenging macroeconomic environment for LTL (less-than-tru...
Neutral
Seeking Alpha
11 days ago
Charles River Laboratories International, Inc. ( CRL ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.
Neutral
Business Wire
11 days ago
STAMFORD, Conn.--(BUSINESS WIRE)--SOLVE, the leading provider of pre-trade data and predictive pricing for fixed income securities markets, today announced a new partnership with Charles River Development, a State Street company, to begin integrating SOLVE's fixed income and predictive pricing capabilities with the Charles River Investment Management Solution (Charles River IMS). The collaborat...
More Charles River Laboratories International, Inc. News

Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Head office United States
CEO James Foster
Employees 19,400
Founded 1947
Website www.criver.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today